The Stanford team developed a versatile injectable alginate-collagen hydrogel, a significant advancement in regenerative medicine and targeted therapeutic delivery.
Stanford researchers have developed a new method for producing high-quality lead-germanium-selenide (PbGeSe) thin films with improved optical performance and uniformity.
Stanford scientists have developed a frequency-based power control method that enables RF amplifiers to double their output power within 500 nanoseconds using only passive components.
Researchers at Stanford have developed a novel T cell engineering platform that leverages constitutively active interleukin-9 receptor (IL-9R) signaling to improve the efficacy and scalability of immunotherapies for solid tumors.
Stanford scientists have developed a new DNA-based technology that allows therapeutic genes to be maintained in human cells for extended periods without altering the cell's chromosomes.
Stanford scientists have discovered a DNA methylation signature on circulating tumor DNA (ctDNA) that can distinguish between the aggressive Leiomyosarcoma (LMS) from its benign counterpart leiomyoma (LM) in the uterus.
Stanford researchers have developed the Large-scale Electrophysiology Amplification Platform (LEAP), a wireless, label-free optical system for monitoring the electrical activity of neurons and heart cells.
Researchers at Stanford have developed an innovative, non-invasive thermal treatment to recover the lost capacity of used lithium-ion batteries (LIBs), offering a scalable and cost-effective solution to the environmental challenges posed by battery waste.
Stanford researchers have developed a novel, multi-specific chimeric antigen receptor (CAR) T-cell therapy designed to overcome the key challenges of treating solid tumors, including tumor heterogeneity, immune evasion, and CAR T-cell exhaustion.
Stanford scientists have developed fully human CD19-targeted CAR T cells designed to overcome the limitations of current CAR T cell therapies, particularly in treating low CD19 density blood cancers.
Stanford researchers developed and patented a multiplexed immunohistochemistry method called multiplexed ion beam imaging (MIBI), which uses antibodies tagged with non-biological elemental isotopes (e.g. rare earth elements) and secondary ion mass spectroscopy.
Riffbot.ai is a web-based platform that leverages AI-powered, customizable chatbots to generate dynamic, personalized self-reflection experiences for learners while providing real-time insights to enhance engagement and improve learning outcomes at scale.
Stanford researchers in Prof. Michelle Monje's lab have developed a method for treating cognitive impairment (aka brain fog) caused by cancer immunotherapy.